Zipalertinib Combo Hits Primary Endpoint in Phase 3 Lung Cancer Trial
CGEM has more than doubled off its 52-week low of $5.68.
Summary
Zipalertinib plus chemotherapy met its primary endpoint of progression-free survival in the Phase 3 REZILIENT3 trial for first-line EGFR exon 20 insertion NSCLC. The interim analysis showed a statistically significant and clinically meaningful PFS improvement, with manageable safety, and the IDMC recommended unblinding. Cullinan and partner Taiho plan to pursue U.S. regulatory approval pending FDA discussions. This is the first positive Phase 3 readout for zipalertinib and a major de-risking event for the program. Full results will be presented at an upcoming medical conference.
At the time of this announcement, CGEM was trading at $19.60 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.3B. The 52-week trading range was $5.68 to $19.94. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: BusinessWire.